SCHEMBL6013090

SCHEMBL6013090

CCCc1cc2ccccc2o1

nearest known ligand 0.60

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.60
AGXT P21549 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HTR2B P41595 7/20 0.46
HTR1A P08908 5/20 0.46
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
CYP19A1 P11511 1/20 0.45
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
TLR8 Q9NR97 1/20 0.44
DRD2 P14416 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1287509 0.89 LOXL2 (0.56) LOXL2AGXTSMN1; SMN2L3MBTL1HTR2B
SCHEMBL29594271 0.89 LOXL2 (0.56) LOXL2AGXTSMN1; SMN2L3MBTL1HTR2B
Hydrochloric Acid SCHEMBL28989961 0.87 LOXL2 (0.55) LOXL2AGXTSMN1; SMN2L3MBTL1HTR2B
SCHEMBL252581 0.87 MAPT (0.60) LOXL2AGXTSMN1; SMN2L3MBTL1HTR2B
SCHEMBL19813189 0.85 MAPT (0.63) LOXL2AGXTSMN1; SMN2L3MBTL1HTR2B
Hydrochloric Acid SCHEMBL27927458 0.85 LOXL2 (0.53) LOXL2AGXTSMN1; SMN2L3MBTL1HTR2B
SCHEMBL10000911 0.85 MAPT (0.63) LOXL2AGXTSMN1; SMN2L3MBTL1HTR2B
SCHEMBL8688187 0.85 MAPT (0.63) LOXL2AGXTSMN1; SMN2L3MBTL1HTR2B
SCHEMBL11243675 0.85 MAPT (0.63) LOXL2AGXTSMN1; SMN2L3MBTL1HTR2B
SCHEMBL31499129 0.83 LOXL2 (0.64) LOXL2AGXTSMN1; SMN2L3MBTL1HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112135825-A Plasma kallikrein inhibitors and uses thereof 夏尔人类遗传性治疗公司 2020-12-25 CN disclosed
US-9783490-B2 Antimicrobial compounds, their synthesis and applications thereof THE SECRETARY OF STATE FOR HEALTH (GB) 2017-10-10 US disclosed
WO-2013129879-A1 GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SK CHEMICALS CO., LTD. (KR) 2013-09-06 WO disclosed
US-7642265-B2 Benzimidazoles and analogs thereof as antivirals ISIS PHARMACEUTICALS, INC. (US) 2010-01-05 US disclosed
US-7408025-B2 Lipopeptides as antibacterial agents CUBIST PHARMACEUTICALS, INC. (US) 2008-08-05 US disclosed
US-7390804-B2 N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-06-24 US disclosed
US-7390804-B2 N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-06-24 US disclosed
WO-2007064914-A2 5-(ARYLSULFONYL)-PYRAZOLOPIPERIDINES ELAN PHARMACEUTICALS, INC. (US) 2007-06-07 WO disclosed
US-7115782-B2 Process for producing aromatic compounds by Friedel-Crafts reaction SHOWA DENKO K.K. (JP) 2006-10-03 US disclosed
WO-2005118545-A1 GAS-PHASE OXIDATION OF ALKYL-SUBSTITUTED HETEROCYCLIC COMPOUNDS BASF AKTIENGESELLSCHAFT (DE) 2005-12-15 WO disclosed
WO-2005118551-A2 THROMBOPOIETIN ACTIVITY MODULATING COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS INC. (US) 2005-12-15 WO disclosed
US-20050222457-A1 Process for producing aromatic compounds by friedel-crafts reaction SHOWA DENKO K.K. (JP) 2005-10-06 US disclosed
EP-1511707-A1 PROCESS FOR PRODUCING AROMATIC COMPOUNDS BY FRIEDEL-CRAFTS REACTION Showa Denko K.K. (JP) 2005-03-09 EP disclosed
WO-2003101925-A1 PROCESS FOR PRODUCING AROMATIC COMPOUNDS BY FRIEDEL-CRAFTS REACTION SHOWA DENKO K. K. (JP) 2003-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222457-A1 Process for producing aromatic compounds by friedel-crafts reaction PAH, DDC, TYR LOXL2 2293/4885AGXT 295/4885SMN1; SMN2 4141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.